DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Parachordoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleParachordoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for parachordoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Parachordoma is a rare soft-tissue tumour; fewer than 100 cases had been reported in the literature as of 2015. The 2015 case report describes a patient whose tumour metastasised rapidly to bone, lung, and intra-abdominal organs. A 2003 report details a 68-year-old man with a left calf parachordoma that invaded surrounding muscle, neurovascular bundles, and bone on MRI. After amputation, widespread metastases to lung, bone, and skin developed. The histology of the primary and metastatic lesions was identical. A 1999 report describes a 21-year-old woman with a painful chest wall parachordoma arising from the fifth intercostal space; she was treated with wide chest wall resection including a 2.5 cm free margin and reconstruction with a Gore-Tex patch and latissimus dorsi flap. That report noted chest wall parachordoma had not previously been described in the medical literature.
No abstract reports any drug treatment, chemotherapy, or radiotherapy for parachordoma. No response rates, survival times, or sample sizes beyond single-case reports are provided. The 2015 case explicitly states that metastatic cases are rare but that this particular tumour was aggressive. The 2003 case confirms that even after amputation, widespread metastasis occurred. The 1999 case does not provide follow-up data on recurrence or metastasis.
What is missing is any clinical trial, any drug tested in parachordoma, any systematic collection of patient outcomes, and any molecular characterisation that might guide patient stratification. Without funding for a registry or a prospective study, the natural history and any potential treatment effects remain unknown.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Computer Assisted Tomography · 2003 · 28 citations
Parachordoma with Multiple Metastases
AbstractWe present a very rare case of parachordoma with local aggressiveness and widespread metastases. A 68-year-old male presented with a mass in his left calf. The lesion was depicted as a poorly marginated mass with inhomogeneous signal intensity on magnetic resonance imaging. The tumor invaded surrounding muscles, neurovascular bundles, and bones. Widespread metastasis to lung, bone, and skin developed after amputation surgery. The histologic features of primary and metastatic lesions were the same and consistent with parachordoma.
European Journal of Cardio-Thoracic Surgery · 1999 · 11 citations · open access
Chest wall parachordoma
AbstractA 21-year-old woman with a painful chest wall mass was found to have a parachordoma (PC). The tumor arose from the fifth intercostal space. A wide chest wall resection including the tumor and a 2.5 cm free margin and the subsequent reconstruction with a Gore-Tex soft tissue patch covered with a latissimus dorsi rotational flap was performed. To our knowledge, chest wall parachordoma has not been previously reported in the medical literature.
International Journal of Hematology and Oncology · 2015 · 0 citations · open access
A Case Report of Aggressive Metastatic Parachordoma.
AbstractParachordoma, first described by Laskowski in 1951, is a rare tumor of soft tissue. Few than 100 cases have been reported in the literature. In 1977 Dabska M. collected 10 cases of parachordoma and he described it as a slow growing, locally invasive tumor.1 Since then, metastatic cases have been described but they are also so rare. In this report, we present a case of parachordoma with an agressive nature, rapidly metastasizing to bone, lung and intraabdominal organs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
